Evaluating the Hepatotoxicity of Compound V with QST/QSP Modeling

Authors: Lakhani VV, Nevarez J
Software: DILIsym®, GastroPlus®
Division: DILIsym Services

Is your compound causing drug-induced liver injury?

Read below how DILIsym Services analyzes the hepatotoxicity of Compound V. You can also watch Vinal Lakhani’s 2021 MIDD+ presentation here.

3 Common Client Questions:

  1. Was their compound responsible for ALT elevations observed during a clinical trial?
  2. If the compound was the primary driver for the cell death and ALT elevations observed, what hepatotoxic mechanisms might their compound be triggering?
  3. To what extent does the compound concentration play a role in the liver?

Our Software Capabilities:

Our quantitative systems toxicology (QST) software DILIsym® investigates the 3 major mechanisms for causing hepatocyte death.

  • BA transporter inhibition
  • Mitochondrial dysfunction
  • Production of reactive oxygen & nitrogen species; i.e. oxidative stress

Our GastroPlus® software builds custom PBBM and PBPK models;

  • To estimate liver concentration of Compound V

What we typically need to proceed:

  • In vitro assays assessing the capability of the molecule to cause cell death
  • PK Data helping determine the liver exposure


Custom QSP development and consulting services are available to anyone, to receive a presentation on how we can help your organization with a fit-for-purpose or disease area QSP platform, please Contact Us.